SubsidieMeestersDevelopment of a natural therapeutic treatment for late-stage lung cancer patients
Celtic Biotech aims to conduct Phase I Part 3 trials for CB24, a home-administered treatment for NSCLC, to secure regulatory approval and establish it as a safe, effective cancer therapy.
Projectdetails
Introduction
Celtic Biotech Ireland has developed CB24 (Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life-changing treatment for Non-Small Cell Lung Cancer (NSCLC).
Mechanism of Action
Delivered intravenously, CB24 induces predictable and consistent apoptosis (cell death) and autophagy (degradation) in human lung carcinoma cells.
Competitive Advantage
CB24 outclasses the competitive NSCLC treatment solutions (surgery, chemotherapy, and radiotherapy) through its:
- Efficacy
- Safety
- Minimal side effects
- Easy-to-use home-based treatment
- Suitability for all patients, including those at stage 3 & 4
Clinical Evidence
Celtic has already proven the efficacy of CB24 through pre-clinical and First-In-Human (FIH) clinical trials.
Project Goals
Through the proposed 24-month EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.855.337 |
Tijdlijn
| Startdatum | 1-10-2023 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- CELTIC BIOTECH LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Novel T cell therapies against lymphocytic leukaemiaCATCH aims to enhance T-cell activation in chronic lymphocytic leukaemia using CAR-T and tri-specific antibodies, while assessing commercial feasibility and developing a business strategy. | ERC Proof of... | € 150.000 | 2022 | Details |
Therapeutic discovery for cholangiocellular carcinomaThe project aims to develop and validate a novel first-in-class therapeutic for cholangiocarcinoma using advanced patient-derived models to improve treatment outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune responseThis project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer. | ERC Proof of... | € 150.000 | 2025 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.
Novel T cell therapies against lymphocytic leukaemia
CATCH aims to enhance T-cell activation in chronic lymphocytic leukaemia using CAR-T and tri-specific antibodies, while assessing commercial feasibility and developing a business strategy.
Therapeutic discovery for cholangiocellular carcinoma
The project aims to develop and validate a novel first-in-class therapeutic for cholangiocarcinoma using advanced patient-derived models to improve treatment outcomes.
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response
This project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer.